What should a Coronavirus Standards Working Group do?

- Assure development and availability of standards, controls, interlab testing, knowledge to support successful rollout & scaling of 2019-nCoV testing
- Identify and develop critical infrastructure to support confidence in test results, interoperability, scale-up, long-term capacity
- Identify best practices that should be institutionalized
  - Learn what we need to do next time we have a global network in place ready to make standards.
17 April Agenda

- Manuscript update
- Communications Strategy update
- Early results from comparisons
  - Heinz Zeichardt, IQVD GmbH
    - INSTAND EQAS 340
  - Alex Marson, UCSF
    - Serological Benchmarking
“We are working together to make sure that the standards, controls, validation tests, and protocols are in place so we can count on test results.

Our work is foundational, and upstream of the existing mechanisms that establish reliability and trustworthiness of results in the diagnostic sector, including regulatory oversight.

This report describes our systematic consideration of the measurement process and how different standards play roles throughout it.”

Join drafting team, 1400PDT today
Communications Strategy Update

Follow-up from Last Week
• Compiling list of communications avenues
• Considered name
  • Standardization
  • International
  • Global
  • “Working Group” – implies action
• Acronyms
• Scope
  • “Emerging virus…”
  • ”COVID”

Near-term Plans
• Develop and roll out preprint
• Coordinate network of communications from the WG
  • provide high-level messaging about the WG and the findings in the preprint
  • use all member’s audiences, channels, vernaculars
• develop FAQs
• press/media outreach (Nature, GenomeWeb, quality news papers,...)
Early results from an interlab study

Prof. Dr. Heinz Zeichhardt
IQVD GmbH
Institut für Qualitätssicherung in der Virusdiagnostik
Berlin

23 March 2020

Extra INSTAND EQAS – Virus Genome Detection (340)

Coronavirus SARS-CoV-2

Deadline for registration: Sunday, 29 March 2020
Deadline for receipt of data: Wednesday, 22 April 2020

Deadline for shipment: Friday, 03 April 2020

Dear colleagues,

Referring to our information of 14 February 2020, INSTAND e.V. wants to inform you on the organizational changes in regard to the EQA scheme for virus genome detection of coronaviruses.

Due to the new epidemiological situation with SARS-CoV-2, INSTAND e.V. in its capacity as reference institution of the German Medical Association as EQA provider will change the EQA schemes for virus genome detection of coronaviruses...
Early results from a serological test comparison

Alex Marson
Associate Professor, UCSF
Scientific Director of Biomedicine, Innovative Genomics Institute (IGI)
Chan Zuckerberg Biohub Investigator

Compare a large population of serological tests using a well-designed panel of ~300 patient samples
All other business

Mailing list – converting to Google Groups (MailChimp too much work)
Communications, planning, engagement, process, operations?
Discussion